This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2001;286:2660.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has conducted a safety review on oral sodium phosphate using the agency's databases and medical literature. The review shows that serious electrolyte disturbances (hypernatremia, hypokalemia, hyperphosphatemia, and hypocalcemia), dehydration, metabolic acidosis, renal failure, tetany, and death have been attributed to patients receiving more than a 45-mL dose of oral sodium phosphate (usually a minimum of 90 mL during a 24-hour period). Changes in hematocrit, serum sodium, blood urea nitrogen, serum osmolality, and body weight after ingesting sodium phosphate oral solution suggest that a mild contraction of intravascular volume can occur in this population.

The FDA review demonstrated that physicians need to be aware that people at increased risk for electrolyte disturbances (eg, patients with congestive heart failure, ascites, renal insufficiency, dehydration, debility, gastrointestinal obstruction, gastric retention, bowel perforation, colitis, megacolon, ileus, or inability to take adequate oral fluid or patients taking diuretics or other medications that affect electrolytes) . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?